NKGen Biotech Inc (NKGN) P/E Multiple
The price action of NKGen Biotech, Inc. (NKGN) securities allows for an assessment of the effectiveness of developing NK-cell-based therapies to combat dementia, where the indicator stands at -0.10. NKGen Biotech, Inc. (NKGN) focuses on creating cellular products in the US and South Korea while protecting its digital intellectual property. Operational activities rely on strict FDA regulations for biomaterial processing, ensuring a baseline level of environmental safety.
Analytical breakdowns for NKGen Biotech, Inc. (NKGN)
- current price and projected stock value:
- market capitalization details:
- company book value details:
- debt and solvency information:
Debt to Equity Ratio NKGen Biotech, Inc.|NKGN - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital NKGen Biotech, Inc.|NKGN - Company Aggregate Debts|Debt to Book Capitalization Ratio NKGen Biotech Inc|NKGN - Company Long-Term Debts|Short-Term Debt Volume NKGen Biotech|Immediate Liquidity nkgenbiotech.com
- earnings and multiples data:
NKGN - Net Income|Future Net Profit NKGen Biotech, Inc.|NKGN - P/E Multiple|Projected Price to Earnings Ratio NKGen|NKGN - PEG Multiple|Enterprise Value to EBITDA Ratio NKGen Biotech Inc|NKGN - Operating profit EBITDA|Earnings per share for the trailing year NKGen Biotech|NKGN - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months nkgenbiotech.com|NKGN - Earnings growth in current year|Consensus forecast of earnings per share growth for next year NKGen Biotech, Inc.
- company sales and revenue statistics:
Summary company analysis:NKGen Biotech
NKGen Biotech, Inc. (NKGN) develops cell therapies for neurodegenerative pathologies in the US and South Korea. The efficacy of clinical trials directly impacts net income, forming the basis for calculating the P/E ratio. This multiple determines the cost per unit of earnings, reflecting investor market expectations. High values indicate a premium for future growth. By analyzing the P/E ratio chart for NKGen Biotech, Inc. (NKGN), one can assess the risk of overpayment amid tight monetary policy.
Key competitors
Price to Earnings Ratio BIIB|P/E Multiple NBIX|Regencell (RGC) - Market Cap to Net Income Ratio|Price to Earnings Ratio axsome.com AXSM|P/E Multiple ACADIA Pharmaceuticals ACAD|XENE - Price to Earnings Ratio|Business Payback Period Viking Therapeutics Inc VKTX|Supernus Pharma (SUPN) - Price to Earnings Ratio|CPRX (Catalyst Pharmaceuticals) - Price to Earnings Ratio|DNLI (denalitherapeutics.com) - P/E Multiple|Price to Earnings Multiple HRMY (Harmony Biosciences Holdings, Inc.)|P/E Multiple BHVN|AMLX (Amylyx Pharmaceuticals Inc) - Company Value to Net Income|P/E Multiple TRVI (Trevi Pharma)|PRAX (Praxis Corp) - Market Cap to Net Income|anavex.com - P/E Multiple|Company Value to Net Income CBLL (CeriBell, Inc.)|PRTA: P/E Multiple|Price to Earnings Multiple ALEC|ANNX (Annexon Biosciences Inc.) - P/E Multiple|omeros.com - Market Cap to Net Income|Price to Earnings Ratio Neurogene (NGNE)|Business Payback Period AC Immune SA|P/E Multiple VYGR (voyagertherapeutics.com)|P/E Multiple Neumora NMRA|Scilex Holding - P/E Multiple|Market Cap to Earnings Tevogen Bio Inc.|Alpha Cognition (ACOG) - Price to Earnings Ratio|cogrx.com (CGTX) - P/E Multiple|Price to Earnings Ratio Inhibikase Therapeutics|Cassava (SAVA) - Business Payback Period|Price to Earnings Ratio Assertio Therapeutics (ASRT)|Business Payback Period Coya|Vistagen - Price to Earnings Ratio|Company Value to Net Income OVID|Acumen Pharmaceuticals Inc. - P/E Multiple|Market Cap to Earnings CervoMed Inc|ATHE: P/E Multiple|Price to Earnings Ratio Clene Nanomedicine|Price to Earnings Ratio PepGen Corp|Jupiter Neurosciences (JUNS) - Business Payback Period|Price to Earnings Ratio Relmada Therapeutics, Inc. (RLMD)|ANVS - Market Cap to Earnings|gracetx.com - Price to Earnings Ratio|AIFF: Price to Earnings Multiple|Klotho Neurosciences - P/E Multiple|NRSN (NeuroSense Therapeutics Ltd.) - Price to Earnings Multiple|Reviva Pharmaceuticals (RVPH) - Price to Earnings Ratio|MTVA (MetaVia Inc.) - Price to Earnings Ratio|Price to Earnings Ratio NeurAxis, Inc|Price to Earnings Ratio HSDT|P/E Multiple PASG|Business Payback Period Neuphoria Therapeutics, Inc.|minervaneurosciences.com - Price to Earnings Ratio|P/E Multiple Athira ATHA|Addex Therapeutics - P/E Multiple|ALZN - P/E Multiple|Cyclerion (CYCN) - Price to Earnings Ratio|Protagenic (PTIX) - P/E Multiple|Price to Earnings Ratio Pasithea|Price to Earnings Multiple CRGT (Cortigent)|Price to Earnings Ratio Avenue Therapeutics (ATXI)|BCLI - Market Cap to Earnings|P/E Multiple CARA (Cara Therapeutics Inc)|CHRO - Price to Earnings Ratio|ELYM: Price to Earnings Ratio|Business Payback Period Intra-Cellular Therapies, Inc. ITCI|Longboard Pharma (LBPH) - Price to Earnings Ratio|Marinus - Company Value to Net Income|Price to Earnings Ratio NeuroBo Pharmaceuticals|SAGE: Company Value to Net Income|P/E Multiple SNPX|Trevena Inc. - Price to Earnings Multiple|Price to Earnings Ratio Vigil Neuroscience, Inc. VIGL|Anew Medical, Inc. - Price to Earnings Ratio|Cerevel Therapeutics - P/E Multiple
